Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 6/20 | 0.46 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.43 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.36 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.36 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL900046 | 0.88 | KMT2A (0.47) | PTGIRPTGDRFABP5FABP7KMT2A | |
| SCHEMBL3822341 | 0.87 | EPHX2 (0.53) | PTGIRPTGDRFABP5FABP7KMT2A | |
| SCHEMBL3820525 | 0.87 | FABP5 (0.46) | PTGIRPTGDRFABP5FABP7KMT2A | |
| SCHEMBL3814521 | 0.86 | EPHX2 (0.41) | PTGIRPTGDRFABP5FABP7KMT2A | |
| SCHEMBL3822541 | 0.86 | PTGIR (0.46) | PTGIRPTGDRFABP5FABP7KMT2A | |
| SCHEMBL3811371 | 0.86 | PTGIR (0.46) | PTGIRFABP5FABP7KMT2AEPHX2 | |
| SCHEMBL27696329 | 0.84 | KMT2A (0.42) | FABP5FABP7KMT2AEPHX2CASP3 | |
| SCHEMBL3812268 | 0.84 | PTGIR (0.48) | PTGIRPTGDRFABP5FABP7KMT2A | |
| SCHEMBL3822175 | 0.84 | KMT2A (0.43) | PTGIRFABP5FABP7KMT2AEPHX2 | |
| SCHEMBL3816301 | 0.83 | KMT2A (0.41) | FABP5FABP7KMT2AEPHX2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1754705-A2 | Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders | Genentech, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1063982-B1 | ANTAGONISTS FOR TREATMENT OF CD11/CD18 ADHESION RECEPTOR MEDIATED DISORDERS | GENENTECH INC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20050203135-A1 | Antagonists for treatment of CD/11CD18 adhesion receptor mediated disorders | GENENTECH, INC. | 2005-09-15 | — | — | US | disclosed |
| CN-1191063-C | Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders | GENENTECH INC (US) | 2005-03-02 | — | — | CN | disclosed |
| CN-1295471-A | Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders | GENENTECH INC (US) | 2001-05-16 | — | — | CN | disclosed |
| EP-1063982-A2 | ANTAGONISTS FOR TREATMENT OF CD11/CD18 ADHESION RECEPTOR MEDIATED DISORDERS | Genentech, Inc. (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999049856-A2 | ANTAGONISTS FOR TREATMENT OF CD11/CD18 ADHESION RECEPTOR MEDIATED DISORDERS | GENENTECH, INC. (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203135-A1 | Antagonists for treatment of CD/11CD18 adhesion receptor mediated disorders | VCAM1, CD58, ITGB8 | PTGIR 343/4885PTGDR 105/4885FABP5 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.